These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37731621)

  • 21. Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
    Clark NF; Taylor-Robinson AW; Heimann K
    Ther Adv Drug Saf; 2022; 13():20420986221107753. PubMed ID: 35898799
    [No Abstract]   [Full Text] [Related]  

  • 22. Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N
    Wen ZH; Wang MM; Li LY; Herdewijn P; Snoeck R; Andrei G; Liu ZP; Liu C
    Bioorg Chem; 2023 Jun; 135():106527. PubMed ID: 37031504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
    Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
    Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
    Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
    mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative docking and molecular dynamics studies of molnupiravir (EIDD-2801): implications for novel mechanisms of action on influenza and SARS-CoV-2 protein targets.
    Istifli ES; Okumus N; Sarikurkcu C; Kuhn ER; Netz PA; Tepe AS
    J Biomol Struct Dyn; 2024 Sep; 42(15):8202-8214. PubMed ID: 37811782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
    Takashita E; Fujisaki S; Morita H; Nagata S; Miura H; Nagashima M; Watanabe S; Takeda M; Kawaoka Y; Hasegawa H
    Antiviral Res; 2023 Aug; 216():105671. PubMed ID: 37451629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD.
    Peter AS; Grüner E; Socher E; Fraedrich K; Richel E; Mueller-Schmucker S; Cordsmeier A; Ensser A; Sticht H; Überla K
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small-Molecule Antiviral β-d-
    Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.
    Ballesteros-Sanabria L; Pelaez-Prestel HF; Ras-Carmona A; Reche PA
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
    Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
    Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
    Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
    He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
    MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity.
    Hadj Hassine I; Ben M'hadheb M; Menéndez-Arias L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum.
    Liang D; Zhang G; Huang M; Wang L; Hong W; Li A; Liang Y; Wang T; Lu J; Ou M; Ren Z; Lu H; Zheng R; Cai X; Pan X; Xia J; Ke C
    Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 RdRp uses NDPs as a substrate and is able to incorporate NHC into RNA from diphosphate form molnupiravir.
    Wang M; Wu C; Liu N; Zhang F; Dong H; Wang S; Chen M; Jiang X; Zhang K; Gu L
    Int J Biol Macromol; 2023 Jan; 226():946-955. PubMed ID: 36528144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.
    Iwamoto M; Duncan KE; Wickremasingha PK; Zhao T; Liberti MV; Lemoine L; Decaesteker T; Rottey S; Maas BM; Gillespie G; Stoch SA
    Clin Transl Sci; 2023 Oct; 16(10):1947-1956. PubMed ID: 37526305
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Ojha D; Hill CS; Zhou S; Evans AB; Leung JM; Lewis CS; Amblard F; Schinazi RF; Baric RS; Peterson KE; Swanstrom R
    bioRxiv; 2023 Aug; ():. PubMed ID: 37662274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.